Evidence map›Paper›PMID 41168445›Full record

ArticleCommunications biology2025

Unveiling and stratifying cell cycle-dependent drug efficacy using a single-cell PLOM-CON approach with correlation anomaly and presage protein signals.

Yoshiyuki Noguchi, Rina Kunishige, Naeko Shinozaki-Narikawa, Hiroshi Yamashita, Kazuyuki Aihara, Masayuki Murata, Fumi Kano

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoshiyuki NoguchiInternational Research Center for Neurointelligence, Institutes for Advanced Study, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Rina KunishigeCell Biology Center, Institute of Integrated Research, Institute of Science Tokyo, Yokohama-shi, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-0343-9735
Naeko Shinozaki-NarikawaCell Biology Center, Institute of Integrated Research, Institute of Science Tokyo, Yokohama-shi, Kanagawa, Japan.
Hiroshi YamashitaGraduate School of Information Science and Technology, Osaka University, Suita-shi, Osaka, Japan.ORCID http://orcid.org/0000-0002-6731-7673
Kazuyuki AiharaInternational Research Center for Neurointelligence, Institutes for Advanced Study, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Masayuki MurataInternational Research Center for Neurointelligence, Institutes for Advanced Study, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Fumi KanoCell Biology Center, Institute of Integrated Research, Institute of Science Tokyo, Yokohama-shi, Kanagawa, Japan. kanou.f.f7f1@m.isct.ac.jp.ORCID http://orcid.org/0000-0002-1903-8733

Funding

Japan Agency for Medical Research and Development (AMED) JP19gm6210015Japan Agency for Medical Research and Development (AMED) JP23gm6410025MEXT | Japan Society for the Promotion of Science (JSPS) JPMJMS2021
6 · The paper itself

Abstract

In drug discovery, assessing and stratifying drug efficacy on cells is vital. To demonstrate the efficacy of drugs on cells in different cell cycle phases, it is essential not only to analyze multidimensional protein data on the single-cell level but also to establish a methodology for extracting key molecules from subtle differences in cellular states in response to the drug. Here we introduce a single cell-PLOM-CON analysis method by combining multiplex immunofluorescence and image-based covariation network analysis and reveal several changes of proteins in early cell state changes across different cell cycle phases in HeLa cells, induced by anticancer drugs, bleomycin, cytarabine and aspirin, before any visible effects of drugs on the cell cycle appeared. Furthermore, the dynamical network biomarker theory reveals that cyclin B1 at the G2 phase is a presage protein signal of S-phase arrest induced by anticancer drugs with modes of action (MoA) similar to cytarabine. This integrated approach allows for the extraction of early protein biomarkers in initial states of drug efficacy and for drug stratification using subtle differences in MoA.

Indexed as

Antineoplastic AgentsCell CycleSingle-Cell AnalysisBleomycinCytarabineHeLa CellsHumansAntineoplastic AgentsBleomycinCytarabine

Identifiers

PMID41168445
PMCPMC12575692

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.